{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Product+A2&page=2", "query": { "intervention": "Product A2", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Product+A2&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T20:05:50.083Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06157853", "title": "Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With a Radiofrequency Microneedling for Facial Rejuvenation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Photoaging", "Wrinkle" ], "interventions": [ { "name": "Radiofrequency Microneedling", "type": "PROCEDURE" }, { "name": "Facial Cleanser", "type": "OTHER" }, { "name": "Facial Moisturizer", "type": "OTHER" }, { "name": "Sunscreen", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Revision Skincare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "35 Years to 65 Years · Female only" }, "enrollment_count": 11, "start_date": "2022-07-11", "completion_date": "2022-08-23", "has_results": false, "last_update_posted_date": "2024-04-10", "last_synced_at": "2026-09-27T20:05:50.083Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06157853" }, { "nct_id": "NCT05845645", "title": "A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Study Participants" ], "interventions": [ { "name": "UCB0599", "type": "DRUG" }, { "name": "Esomeprazole", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 73, "start_date": "2023-05-31", "completion_date": "2024-04-13", "has_results": true, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-09-27T20:05:50.083Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05845645" }, { "nct_id": "NCT00554853", "title": "PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "pioglitazone", "type": "DRUG" }, { "name": "Sublingual nitroglycerine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "21 Years to 100 Years" }, "enrollment_count": 143, "start_date": "2007-11", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2017-02-02", "last_synced_at": "2026-09-27T20:05:50.083Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00554853" }, { "nct_id": "NCT03899155", "title": "Pan Tumor Rollover Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Regorafinib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1500, "start_date": "2019-08-09", "completion_date": "2029-08-25", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-09-27T20:05:50.083Z", "location_count": 59, "location_summary": "Huntsville, Alabama • Tucson, Arizona • Lynwood, California + 46 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Lynwood", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03899155" }, { "nct_id": "NCT04410198", "title": "Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia Associated With End Stage Renal Disease (ESRD)" ], "interventions": [ { "name": "Roxadustat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 203, "start_date": "2020-05-26", "completion_date": "2021-10-11", "has_results": true, "last_update_posted_date": "2022-09-13", "last_synced_at": "2026-09-27T20:05:50.083Z", "location_count": 9, "location_summary": "Englewood, Colorado • Caldwell, Idaho • Baton Rouge, Louisiana + 6 more", "locations": [ { "city": "Englewood", "state": "Colorado" }, { "city": "Caldwell", "state": "Idaho" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Kalamazoo", "state": "Michigan" }, { "city": "Tupelo", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT04410198" }, { "nct_id": "NCT06560684", "title": "CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tenofovir" ], "interventions": [ { "name": "Oral F/TDF Pills", "type": "DRUG" }, { "name": "TFV rectal douche", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 150, "start_date": "2024-10-29", "completion_date": "2026-06-16", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-27T20:05:50.083Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Los Angeles, California • Lawrenceville, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lawrenceville", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06560684" }, { "nct_id": "NCT02395822", "title": "MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia" ], "interventions": [ { "name": "IL-15", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 17, "start_date": "2015-10-01", "completion_date": "2016-12-01", "has_results": true, "last_update_posted_date": "2018-02-20", "last_synced_at": "2026-09-27T20:05:50.083Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02395822" }, { "nct_id": "NCT03421353", "title": "AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours" ], "interventions": [ { "name": "AZD9150", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-Flourouracil", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 76, "start_date": "2018-02-07", "completion_date": "2024-03-28", "has_results": false, "last_update_posted_date": "2024-08-21", "last_synced_at": "2026-09-27T20:05:50.083Z", "location_count": 6, "location_summary": "Lafayette, Indiana • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more", "locations": [ { "city": "Lafayette", "state": "Indiana" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03421353" }, { "nct_id": "NCT04103645", "title": "Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Vactosertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2019-11-22", "completion_date": "2024-07-10", "has_results": true, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-09-27T20:05:50.083Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04103645" }, { "nct_id": "NCT01349595", "title": "Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Disorder of Transplanted Kidney" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mark Stegall", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 4, "start_date": "2011-12", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-09-27T20:05:50.083Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01349595" } ] }